Therefore, our findings reveal a critical role for TDO2-Kyn-AhR signalling in ADT-induced tumour dormancy and recurrence in prostate cancer and suggest a new therapeutic target for androgen-sensitive prostate cancer by combining ADT with targeting the TDO2-Kyn-AhR pathway. Here, TDO2 is linked to prostate cancer.